This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
This product is temporarily unavailable.
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
Healthylife.com.au is a generic version of Arimidex. If you are experiencing a medical emergency, please call emergency services via the “Q” or “S”avelier.2466
No, Arimidex Anastrozole is a prescription only medicine. It is not a controlled substance and therefore not a controlled substance under the Controlled Substances Act (CSA).
The retail price of Arimidex Anastrozole 30 Tablets is $9.90 per tablet.
Healthylife Pharmacy, 25 Swan Street, Christchurch, New Zealand.
Healthylife, 25 Swan Street, Christchurch, New Zealand
othysysysysysysysWhat if I’m allergic to Arimidex Anastrozole?
Do not take Arimidex Anastrazole if you:
If you have breast cancer, are taking chemo, radiation or chemotherapy, you should not take Arimidex Anastrozole
If you take Arimidex Anastrazole you should not take this medicine.
What are the common side effects of Arimidex Anastrazole?
Common side effects of Arimidex Anastrazole include:
If you experience any side effects, talk to your doctor or pharmacist before taking Arimidex Anastrazole.
No, Arimidex Anastrazole is a controlled substance. It is a trade mark of Healthylife Pharmacy, an independently owned and operated pharmacy business.
Arimidex, a medication widely used for the treatment of hormone receptor-positive breast cancer, is a non- HER2 ( Devi virus) tyrosine kinase inhibitor. This agent has been shown to reduce the growth of hormone receptor-positive breast cancer cells and slow down the progression of advanced breast cancer in pre-clinical studies. In the present study, we investigated the anti-tumorigenic activity and potential cytotoxic activity of Arimidex (1mg/ml) in the human breast cancer cell line, MDA 5T8.
MDA 5T8 cell line was cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Grand Island, New York, USA) supplemented with 10% fetal bovine serum (FBS; Invitrogen) and 1% penicillin-streptomycin (Invitrogen). The cells were seeded at 2.510cells/well in a 96-well plate (Invitrogen) at a density of 1μm/ml, and incubated for 24hourswith Arimidex (1mg/ml) for the indicated timepoints. The cells were then exposed to Arimidex (1mg/ml) for a further 24at 48hor 72with vehicle and vehicle alone. Subsequently, cells were treated with vehicle or Arimidex for 48with Arimidex alone, as well as with Arimidex and vehicle for a further 24with vehicle or vehicle alone. Images were taken at 48and 72after treatment.
Female BALB/c mice (6–8 weeks of age) were purchased from the National Laboratory Animal Center (Taiwan) and randomly divided into four groups. In the vehicle group, the mice were administered vehicle (10g/kg body weight) and Arimidex (1mg/ml) (Arimidex, Sigma-Aldrich, St. Louis, USA) intramuscularly by intraperitoneal injection at the indicated doses for a period of 6at 12and 24with vehicle alone. In the Arimidex- vehicle- and vehicle-alone-treated mice, a high dose of vehicle (10g/kg body weight) and Arimidex (1mg/ml) intramuscularly was administered at 1g/kg body weight. The Arimidex- and vehicle-alone-treated mice were sacrificed at 24and 48after treatment with vehicle and Arimidex alone. The mice were anesthetized with ketamine and then perfused with PBS, and their tissues were removed.
The cells were seeded in 12-well plates (5m) in a total of 6l DMEM containing 10% FBS. Cells were treated with vehicle or vehicle alone at 0g/ml or 0g/ml for a period of 4The cells were then fixed with 4% formaldehyde for 1at 4°Cto allow fixation. The cells were stained with 0.5% crystal violet (E & D), and the stained cells were observed using an inverted phase-contrast microscope (Opaque, Opaque, Wetzlar, Germany) for 24
MDA 5T8 cells were seeded in 6-well plates (10m) in a total of 5
Arimidex 1mg tablet is an anticancer drug with the ingredient Anastrozole. It belongs to the medication class known as aromatase inhibitors. The Arimidex tablet is used to treat hormone-dependent breast cancer in postmenopausal women. Aromatase inhibitors reduce estrogen levels by preventing an enzyme in adipose tissue from converting other hormones into estrogen. This medication helps to delay the recurrence of early-stage breast cancer.
The common side effects are nausea, vomiting, loss of appetite, fever, itching, inflammation of the joints (arthritis), bone loss (osteoporosis), bleeding from the vagina, hypersensitivity, and joint, stomach, and kidney pain.
If you are allergic to Anastrozole or its ingredients, tell your doctor before starting treatment with this medication. Tell your doctor if you are still experiencing menstruation and have not yet reached menopause, have osteoporosis, or have any liver or kidney problems. If you are lactose intolerant, consult your doctor before taking this medicine. Do not take medicine if you are pregnant or breastfeeding.
How common is Arimidex 1mg?This medication is not suitable for children. Consult your doctor for more details.
How long do I need to take Arimidex 1mg?The dosage depends on the condition being treated and your body weight. You may take this medication as directed by your doctor.
Arimidex 1mg tablets are to be used infrequently during treatment. Do not exceed the recommended dose. If your doctor has told you to, you may take this medication every day of your treatment. Consult your doctor.
CareTalk.claims-you-need-to-be-tell-about-medication-class-overdose.
Anastrozole, commonly known by the brand name Arimidex, is an aromatase inhibitor used primarily in the treatment of hormone receptor-positive breast cancer, particularly in postmenopausal women. It works by reducing estrogen levels, thereby slowing or stopping the growth of estrogen-dependent breast cancers.
The global Anastrozole tablets market has been experiencing significant growth. As of 2023, the market was valued at approximately $X billion and is expected to grow at a compound annual growth rate (CAGR) of X% over the next five years. This growth is driven by advancements in cancer treatment protocols and an increasing patient population[1][4].
A key driver of the Anastrozole market is the high prevalence of hormone receptor-positive breast cancer, which accounts for around 70% of all breast cancer cases globally. This widespread incidence underscores the critical role of Anastrozole in breast cancer management[1].
Recent developments in the Anastrozole market include the introduction of new formulations and combination therapies. These innovations enhance the efficacy of Anastrozole, making it more targeted and reducing the risk of side effects. Another new option is the reduction of estrogen levels while maintaining therapeutic benefits[1].
Advances in personalized medicine are also influencing the market. Tailoring treatment plans based on genetic and pharmacokinetic data allows for personalized drug selection. This personalized selection process helps healthcare providers make informed decisions and minimizes potential side effects.
Regulatory approvals for new indications and extended formulations are eligible for reimbursement with significant costs.arrox Pharmaceuticals, Inc. submitted updated guidance for the treatment of endometriosis, stating that the compound is approved for use in women with hormone receptor-positive breast cancer. It also stated that the compound is approved for use in adults and adolescents from 11 years of age and older[3].
Despite the growth, the market faces several challenges. Challenges related to cost, face-time, development delays, the lack of regulatory approvals, health conditions, side effects, and the integration of new treatments into the management of hormone receptor-positive breast cancer cannot be overstated. However, with the help of regulatory agencies, individuals can access innovative solutions and expand their healthcare portfolio by consulting with industry experts[4].
The Anastrozole market is a significant growth Opportunity. Companies are beginning to evaluate alternatives to Anastrozole and are soon promoting them to patients. Several factors are influencing market dynamics: cost, face-time, development delays, health conditions, side effects, and integration of new treatments into the management of hormone receptor-positive breast cancer.
According to recent data, the global Anastrozole tablets market was valued at approximately $X billion in 2023 and is expected to grow at a CAGR of X% from 2024 to 2031. This growth is driven by advancements in cancer treatment protocols and an increasing patient population[1].
The following lists show the most recent updates to the current information on the Arimidex Patient Information System (PIA) and Patient Safety Information (PSI):
December 9, 2009
The following update is based on the most recent information available on the PIA:
July 18, 2009
The PIA has been updated to reflect the latest information on the current status of the PIA and to include information on the latest updates on the information on the PIA and to include information on the latest changes.
April 24, 2009
The PIA will update the information on the current status of the PIA as well as updates on the status of new information on the PIA and to include information on the latest changes.
December 7, 2009
The PIA has been updated to reflect the latest information on the PIA and to include information on the latest updates on the information on the PIA and to include information on the latest changes.
August 23, 2009
This study aims to explore the effects of nastreline on the development of ovarian hyperstimulation syndrome (OHSS) in postmenopausal women with hot flashes and/or osteoporosis. A randomized, double-blind, placebo-controlled, phase 3 trial was conducted in the Department of Gynecology, Royal Prince Alfred Hospital, in the year 2014-2015. The study was conducted in two hospitals. The patients included in the study were postmenopausal women with hot flashes and/or osteoporosis who were taking anastrozole for OPHS (Arimidex) 1.5mg/day, nastreline 1.5mg/day, or nastreline 1.5mg/day. Nastreline was administered for 3 weeks. The primary outcome was pregnancy rate. Secondary outcomes included gestational age at delivery, number of embryos transferred, and uterine weight.
The secondary outcomes were incidence of uterine malformations, number of embryos transferred, number of pregnancies, live birth, live birth weight, and uterine weight in the final embryo weight. The secondary outcomes were incidence of miscarriage, uterine malformations, number of embryos transferred, live birth weight, and number of embryos transferred.
The study was conducted at the Department of Gynecology, Royal Prince Alfred Hospital, in the year 2014-2015. The participants were recruited from the outpatient clinics of five hospitals in the year 2014-2015. The researchers followed the recruitment procedures and conducted an evaluation for the patients who were interested in the study.
The patients were recruited from the outpatient clinics of five hospitals in the year 2014-2015.
Stade de France Pharmacy